1 duplicate copy in the archive
EFTA Document EFTA01450729
Title Matchefta-efta01450729
Case Filesd-10-EFTA01450729Dept. of JusticeEFTA Document EFTA01450729
Unknown1p
Case File
sd-10-EFTA01450729Dept. of JusticeEFTA Document EFTA01450729
Other
William Blair & Company, LLC. Exhibit 1 ARIAD Pharmaceuticals, Inc. Sum-of-Parts Fair Value (dollars in thousands) Drug Peak Sales Stage of Development Estimated Launch Date Probability of Commercialization Percentage of Sales to Company Probability. Adjusted NPV Value per Share Percentage of Fair Value Iclusig-CML 9746.822 Marketed January 2013/ 100% 100% $1,843,975 $9.85 83.4% Worldwide July 2013 AP28113-ALK* NSCLC S280918 Phase Ifl I 1-12 2016 81% 100% $3
Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01450729
Pages
1
Persons
0
Integrity
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.